U.S. Markets close in 1 hr 44 mins
  • S&P 500

    3,858.43
    +6.58 (+0.17%)
     
  • Dow 30

    31,226.48
    +38.10 (+0.12%)
     
  • Nasdaq

    13,537.86
    +80.62 (+0.60%)
     
  • Russell 2000

    2,144.77
    -15.85 (-0.73%)
     
  • Crude Oil

    53.15
    -0.16 (-0.30%)
     
  • Gold

    1,867.70
    +1.20 (+0.06%)
     
  • Silver

    25.94
    +0.17 (+0.68%)
     
  • EUR/USD

    1.2162
    +0.0047 (+0.3892%)
     
  • 10-Yr Bond

    1.1060
    +0.0160 (+1.47%)
     
  • Vix

    21.45
    -0.13 (-0.60%)
     
  • GBP/USD

    1.3719
    +0.0064 (+0.4692%)
     
  • USD/JPY

    103.5230
    -0.0470 (-0.0454%)
     
  • BTC-USD

    31,934.55
    -3,017.12 (-8.63%)
     
  • CMC Crypto 200

    632.80
    -47.11 (-6.93%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Allena Pharmaceuticals Enters Oversold Territory

Zacks Equity Research
Verizon and AT&T recently reported third-quarter results, putting focus on telecom ETFs.

Allena Pharmaceuticals, Inc. ALNA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ALNA given that, according to its RSI reading of 26.01, it is now in oversold territory.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet, ALNA’s low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Allena Pharmaceutical’s earnings consensus.

Over the past two months, investors have seen 1 earnings estimate revision move higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for ALNA has also been on an upward trend over the past 60 days, as estimates have risen by 10.9% over the last two months.

If this wasn’t enough, Allena Pharmaceuticals also has a Zacks Rank #2 (Buy) which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Allena Pharmaceuticals, Inc. (ALNA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research